Deals
Catalyst Said to Weigh Sale, IPO of Therapure Units
- Drugmaker’s contract development unit may fetch C$400 million
- Sale has attracted interest from buyout firms, drugmakers
This article is for subscribers only.
Private equity firm Catalyst Capital Group Inc. is exploring options for Canadian pharmaceutical company Therapure Biopharma Inc., a year after it postponed plans for an initial public offering, people with knowledge of the matter said.
Catalyst has hired Wells Fargo & Co. to help find a buyer for the contract development and manufacturing part of its business, which could fetch more than C$400 million ($302 million), the people said, asking not to be identified because the deliberations are private.